Treatment Information

Cancer Monthly > Treatment Information
Back

Prostate Cancer treatment details. Biologic therapy.

Massachusetts General Hospital, Boston, Mass, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Boston, Mass
Treatments:Biologic therapyHospital:Massachusetts General Hospital
Drugs:Journal:Link
Date:Jun 2006

Description:

Patients: This phase II study involved 44 men with metastatic prostate cancer. The men were divided into two groups of 22 patients, group 1 and group 2. The mean age of group 1 was 75.6 years (ranging from 54-88) and group 2 was 72.7 (ranging from 56-88).

Treatment: Group 1 received astrasentan alone, and group 2 received a combination of a biological agent astrasentan (a selective endothelin-A receptor antagonist) and zolendronic acid. After 12 weeks, the men in both groups that were still in the study received the combination therapy.

Toxicity: One man in each group experienced grade 3 edema and dyspnea and stopped therapy, after which their symptoms improved. Two serious adverse events occurred (myocardial infarction and gastrointestinal bleeding) but were considered unrelated to the treatment. The occurrence of myalgias, bone pain, and fever were more common in group 2, while edema was more common in group 1.

Results: This therapy had minimal clinical efficacy with no objective responses. Most patients had disease progression when examined 12 weeks after therapy. One patient receiving astrasentan alone (group 1) had an improvement in his prostrate-specific antigen response.

Support: This study was supported in part by Abbot Laboratories, which provided the astrasentan.

Correspondence: Dr. M. Dror Michaelson




Email Physician More Information


Back